CLINICAL GUIDELINES AND CONSENSUSES |
|
Popkova T.V., Panafidina T.A., Lila A.M.
Methodological recommendations (draft). Systemic lupus erythematosus: Diagnosis, treatment, monitoring (short version)
|
8-15 |
ORIGINAL STUDIES |
|
Bashkinov R.A., Mazurov V.I., Gaydukova I.Z., Inamova O.V., Petrova M.S.
Features of the course of osteoarthritis in patients with asymptomatic hyperuricemia
|
16-28 |
|
Morozova K.P., Mazurov V.I., Velikanova L.I., Melnikov E.S.
Effect of exogenous glucocorticosteroids on adrenal steroidogenesis in patients with rheumatoid arthritis
|
29-36 |
|
Musiychuk M.M., Gaydukova I.Z., Mazurov V.I., Inamova O.V., Aliev D.B., Lapin S.V.
Impact of hyperuricemia at the clinical course of systemic lupus erythematosus and comorbid conditions in young and middle-aged female patients
|
37-46 |
|
Trofimov E.A., Mazurov V.I., Makhortova S.A., Samigullina R.R., Shostak M.S., Trofimova A.S.
Safety of biological and targeted therapy for the risk of malignant neoplasms arising
|
47-54 |
|
Melnikov E.S., Morozova K.P.
Comparative analysis of cardiovascular risk scores in patients with rheumatoid arthritis combined with thrombocytosis and normal platelet level
|
55-63 |
|
Shokhin A.A., Trofimova A.S., Trofimov E.A.
Possibilities of local injection therapy for work-associated knee osteoarthritis
|
64-73 |
|
Tsinzerling A.Yu., Mazurov V.I., Inamova O.V., Petrova M.S., Gaydukova I.Z.
Comorbid conditions in patients with psoriatic arthritis and hyperuricemia
|
74-80 |
|
Gaydukova I.Z., Petukhova A.A., Bombina M.V., Bandurko E.P., Inamova O.V., Mazurov V.I.
Aseptic necrosis in the practice of a therapist – treatment efficacy based on one-year period of observation
|
81-94 |
|
Yudkina N.N., Volkov A.V.
How to avoid missing a systemic sclerosis sine scleroderma in a patient with pulmonary arterial hypertension
|
95-102 |
|
Oleinik V.S., Davydova E.V.
Influence of vibro-hazardous production at the clinical course of diabetes mellitus type 2
|
103-107 |
|
Koroy P.V., Yagoda A.V., Dudov T.R.
The importance of matrix metalloproteinases and their inhibitors in predicting F4 fibrosis (cirrhosis) in case of chronic hepatic disorders
|
108-115 |
REVIEWS |
|
Mazurov V.I., Tyrenko V.V., Vakhlevsky V.V.
Problems of cardiommunology in the clinic of internal medicine
|
116-124 |
|
Konovalova D.Yu., Lebedev P.A., Zharkov M.N.
The importance of skin autofluorescence parameter in stratification of risk of mortality and cardiovascular events in patients receiving programmed hemodialysis
|
125-133 |
GUIDELINES FOR PRACTITIONERS |
|
Chumovatov N.V., Ainsanova A.A., Chernykh N.A., Khozikov A.S., Komissarova O.G.
Active tuberculosis process in female patient with asymptomatic clinical course of malignant neoplasm in the pulmonary tissue
|
134-139 |
LECTURE |
|
Starovoytova M.N., Desinova O.V.
Raynaud’s syndrome: Clinical picture, diagnostics, therapeutic approaches
|
140-148 |
|
Mironchev A.O., Isaev M.R., Mironchev O.V.
Exocrine pancreatic insufficiency – behind the veil of chronic pancreatitis and more. Part 2: Modern approaches to diagnosis and treatment
|
150-159 |
|
Didigova R.T., Evloeva D.A., Shadyzheva Kh.I., Malsagova Kh.A., Merzhoev L.-A.D., Buzurtanova Kh.M.
Chronic pancreatitis: Diagnosis and treatment
|
160-164 |
Guideline for practitioners |
|
Mubarakshina O.A., Batishcheva G.A., Dronova Yu.M., Chernov S.Yu.
Patient with overactive urinary bladder at a therapist’s appointment: Algorithm of assistance
|
166-176 |
ACTUAL ISSUES OF PHARMACOTHERAPY AND PREVENTIVE TREATMENT |
|
Gaydukova I.Z., Mazurov V.I.
Intra-articular introduction of hyaluronic acid in patients with early osteoarthritis
|
177-182 |
|
Ketova G.G., Shamina O.M., Dolgushina A.I.
Modern proton pump inhibitors: Clinical advantages of esomeprazole
|
184-190 |
Activities of RNMOT |
|
Digest of interregional scientific and practical events under the aegis or with the participation of RSMSIM (January – February 2025)
|
192-194 |
JUBILEE |
|
To the anniversary of academician of RAS Vadim Ivanovich Mazurov
|
195 |
Русский
